Spots Global Cancer Trial Database for quizartinib
Every month we try and update this database with for quizartinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | NCT04209725 | Leukemia, Myelo... | CPX-351 Quizartinib | 18 Years - 80 Years | SCRI Development Innovations, LLC | |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01892371 | FLT3 Gene Mutat... FLT3 Internal T... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Cytarabine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | NCT02039726 | AML | Quizartinib Salvage Chemoth... | 18 Years - | Daiichi Sankyo | |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04047641 | Acute Myeloid L... Blasts 20 Perce... High Risk Myelo... Recurrent Acute... Recurrent Acute... Recurrent High ... Refractory Acut... Refractory High... | Cladribine Cytarabine Idarubicin Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | NCT04107727 | Acute Myeloid L... | Quizartinib Placebo oral ta... Cytarabine Idarubicin | 18 Years - 70 Years | PETHEMA Foundation | |
| A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | NCT04209725 | Leukemia, Myelo... | CPX-351 Quizartinib | 18 Years - 80 Years | SCRI Development Innovations, LLC | |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT02834390 | Acute Myeloid L... | Quizartinib Cytarabine Idarubicin Daunorubicin | 20 Years - 75 Years | Daiichi Sankyo | |
| Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | NCT03793478 | Acute Myeloid L... | Quizartinib Fludarabine Cytarabine Intrathecal (IT... Etoposide | 1 Month - 21 Years | Daiichi Sankyo | |
| Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT03723681 | Acute Myeloid L... | Quizartinib | 18 Years - 70 Years | Daiichi Sankyo | |
| Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | NCT04687761 | Leukemia, Myelo... De Novo Age More 60yr | Azacitidine Venetoclax Quizartinib Cytarabine Venetoclax Quizartinib | 60 Years - | PETHEMA Foundation | |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT03661307 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... | Decitabine Quizartinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | NCT04128748 | Acute Myeloid L... Blasts More Tha... High Risk Myelo... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Liposome-encaps... Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) | NCT02668653 | Acute Myeloid L... Leukemia | Chemotherapy Quizartinib Placebo | 18 Years - 75 Years | Daiichi Sankyo | |
| A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment | NCT04112589 | Acute Myeloid L... | Quizartinib Fludarabine Cytarabine Idarubicin glycosylated G-... | 18 Years - 70 Years | PETHEMA Foundation | |
| Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | NCT04687761 | Leukemia, Myelo... De Novo Age More 60yr | Azacitidine Venetoclax Quizartinib Cytarabine Venetoclax Quizartinib | 60 Years - | PETHEMA Foundation | |
| Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT03723681 | Acute Myeloid L... | Quizartinib | 18 Years - 70 Years | Daiichi Sankyo | |
| Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | NCT04107727 | Acute Myeloid L... | Quizartinib Placebo oral ta... Cytarabine Idarubicin | 18 Years - 70 Years | PETHEMA Foundation | |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment | NCT04112589 | Acute Myeloid L... | Quizartinib Fludarabine Cytarabine Idarubicin glycosylated G-... | 18 Years - 70 Years | PETHEMA Foundation | |
| A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) | NCT01468467 | Leukemia, Myelo... | AC220 | 18 Years - | Daiichi Sankyo | |
| A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT01390337 | Leukemia, Myelo... | AC220 daunorubicin cytarabine | 18 Years - 60 Years | Daiichi Sankyo | |
| Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) | NCT02668653 | Acute Myeloid L... Leukemia | Chemotherapy Quizartinib Placebo | 18 Years - 75 Years | Daiichi Sankyo | |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01892371 | FLT3 Gene Mutat... FLT3 Internal T... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Cytarabine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT02834390 | Acute Myeloid L... | Quizartinib Cytarabine Idarubicin Daunorubicin | 20 Years - 75 Years | Daiichi Sankyo |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
